VulnerabilityModified
CVE-2022-45611
An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.
CRITICAL 9.8EPSS 1.18%
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (1.18%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.
- CVSS 3.1
- 9.8 CRITICALCVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 1.18% probability · 66th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-522
- Affected
- fresenius-kabi/pharmahelp firmware
- Source
- cve@mitre.org
References
- https://www.fresenius-kabi.com/de-at/produkte/pharmahelp-compounderProduct
- https://www.fresenius.com/sites/default/files/2023-11/Fresenius%20-%20CVE-2022-45611.pdf
- https://www.fresenius.com/sites/default/files/2023-12/Fresenius%20-%20CVE-2022-45611.pdf
- https://www.fresenius-kabi.com/de-at/produkte/pharmahelp-compounderProduct
- https://www.fresenius.com/sites/default/files/2023-11/Fresenius%20-%20CVE-2022-45611.pdf
- https://www.fresenius.com/sites/default/files/2023-12/Fresenius%20-%20CVE-2022-45611.pdf
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.